Moreover, with regard to the RANKL pathway, serum levels of sRANKL in RA patients did not show any differences during 15 months of anti-TNF-α therapy (p = 0.281; Figure 3a). The gene discussed is TNFSF11; the disease is rheumatoid arthritis.